200 related articles for article (PubMed ID: 17200487)
1. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
NINDS NET-PD Investigators
Neurology; 2007 Jan; 68(1):20-8. PubMed ID: 17200487
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
NINDS NET-PD Investigators
Neurology; 2006 Mar; 66(5):664-71. PubMed ID: 16481597
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
[TBL] [Abstract][Full Text] [Related]
4. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Shults CW; Oakes D; Kieburtz K; Beal MF; Haas R; Plumb S; Juncos JL; Nutt J; Shoulson I; Carter J; Kompoliti K; Perlmutter JS; Reich S; Stern M; Watts RL; Kurlan R; Molho E; Harrison M; Lew M;
Arch Neurol; 2002 Oct; 59(10):1541-50. PubMed ID: 12374491
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of coenzyme Q10 in patients with Parkinson's disease.
Jiménez-Jiménez FJ; Molina JA; de Bustos F; García-Redondo A; Gómez-Escalonilla C; Martínez-Salio A; Berbel A; Camacho A; Zurdo M; Barcenilla B; Enríquez de Salamanca R; Arenas J
J Neural Transm (Vienna); 2000; 107(2):177-81. PubMed ID: 10847558
[TBL] [Abstract][Full Text] [Related]
8. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
Shults CW; Flint Beal M; Song D; Fontaine D
Exp Neurol; 2004 Aug; 188(2):491-4. PubMed ID: 15246848
[TBL] [Abstract][Full Text] [Related]
10. WITHDRAWN: Coenzyme Q10 for Parkinson's disease.
Liu J; Wang LN; Zhan SY; Xia Y
Cochrane Database Syst Rev; 2012 May; 2012(5):CD008150. PubMed ID: 22592726
[TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease.
Müller T; Büttner T; Gholipour AF; Kuhn W
Neurosci Lett; 2003 May; 341(3):201-4. PubMed ID: 12697283
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Huntington Study Group
Neurology; 2001 Aug; 57(3):397-404. PubMed ID: 11502903
[TBL] [Abstract][Full Text] [Related]
13. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.
Levy G; Kaufmann P; Buchsbaum R; Montes J; Barsdorf A; Arbing R; Battista V; Zhou X; Mitsumoto H; Levin B; Thompson JL
Neurology; 2006 Mar; 66(5):660-3. PubMed ID: 16534103
[TBL] [Abstract][Full Text] [Related]
14. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
Parashos SA; Swearingen CJ; Biglan KM; Bodis-Wollner I; Liang GS; Ross GW; Tilley BC; Shulman LM;
Arch Neurol; 2009 Sep; 66(9):1099-104. PubMed ID: 19597081
[TBL] [Abstract][Full Text] [Related]
15. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease.
Elble RJ; Suchowersky O; Shaftman S; Weiner WJ; Huang P; Tilley B;
Mov Disord; 2010 Jun; 25(8):1082-6. PubMed ID: 20131372
[TBL] [Abstract][Full Text] [Related]
16. Coenzyme Q10.
Med Lett Drugs Ther; 2006 Feb; 48(1229):19-20. PubMed ID: 16498307
[No Abstract] [Full Text] [Related]
17. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome.
Young JM; Florkowski CM; Molyneux SL; McEwan RG; Frampton CM; Nicholls MG; Scott RS; George PM
Am J Hypertens; 2012 Feb; 25(2):261-70. PubMed ID: 22113168
[TBL] [Abstract][Full Text] [Related]
19. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
Shults CW; Haas RH; Beal MF
Biofactors; 1999; 9(2-4):267-72. PubMed ID: 10416040
[TBL] [Abstract][Full Text] [Related]
20. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic.
Horstink MW; van Engelen BG
Arch Neurol; 2003 Aug; 60(8):1170-2; author reply 1172-3. PubMed ID: 12925381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
